• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮肝胆道引流术对恶性高位胆管梗阻性高胆红素血症患者血清基质金属蛋白酶-9 酶活性的影响。

Effect of Percutaneous Biliary Drainage on Enzyme Activity of Serum Matrix Metalloproteinase-9 in Patients with Malignant Hilar Obstructive Hyperbilirubinemia.

机构信息

Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.

Center for Radiology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.

出版信息

Medicina (Kaunas). 2023 Feb 10;59(2):336. doi: 10.3390/medicina59020336.

DOI:10.3390/medicina59020336
PMID:36837539
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9958900/
Abstract

. Cholestasis activates complex mechanisms of liver injury and as a result has an increased production of matrix metalloproteinases (MMP). Depending on the stage of liver disease, different matrix metalloproteinases expressions have been detected and could serve as indirect biomarkers as well as therapeutic targets. MMP-9 proteolytic activity has a proven role in both liver regeneration and neoplastic cell invasion in various malignancies. The purpose of this prospective cohort study was to evaluate the effect of external biliary drainage on enzyme activity of MMP-9 in the serum of patients with malignant hilar biliary obstruction. . Between November 2020 and April 2021, 45 patients with malignant hilar biliary obstruction underwent percutaneous biliary drainage following determination of serum MMP-9 enzyme activity (before treatment and 4 weeks after the treatment) by gelatin zymography. . MMP-9 values decreased statistically significantly 4 weeks after percutaneous biliary drainage ( = 0.028) as well as the value of total bilirubin ( < 0.001), values of direct bilirubin ( < 0.001), aspartate aminotransferase (AST) ( < 0.001), alanine transaminase (ALT) ( < 0.001), and gamma-glutamyl transferase (GGT) ( < 0.001). . In patients with malignant hilar biliary obstruction treated by external percutaneous biliary drainage for cholestasis resolution, a significant reduction in MMP-9 serum values was noted 4 weeks after the treatment.

摘要

. 胆汁淤积激活了肝脏损伤的复杂机制,因此基质金属蛋白酶 (MMP) 的产生增加。根据肝病的阶段,已经检测到不同的基质金属蛋白酶表达,它们可以作为间接生物标志物和治疗靶点。MMP-9 的蛋白水解活性已被证明在各种恶性肿瘤中对肝脏再生和肿瘤细胞侵袭都有作用。本前瞻性队列研究的目的是评估外引流对恶性肝门部胆管梗阻患者血清 MMP-9 酶活性的影响。. 2020 年 11 月至 2021 年 4 月,45 例恶性肝门部胆管梗阻患者在确定血清 MMP-9 酶活性(治疗前和治疗后 4 周)后,通过明胶酶谱法进行经皮胆道引流。. 经皮胆道引流 4 周后 MMP-9 值统计学显著降低(=0.028),总胆红素(<0.001)、直接胆红素(<0.001)、天门冬氨酸氨基转移酶(AST)(<0.001)、丙氨酸氨基转移酶(ALT)(<0.001)和γ-谷氨酰转移酶(GGT)(<0.001)值也降低。. 在因胆汁淤积而行外引流治疗的恶性肝门部胆管梗阻患者中,治疗 4 周后血清 MMP-9 值显著降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4255/9958900/ea5a07d94414/medicina-59-00336-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4255/9958900/97eee23563c3/medicina-59-00336-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4255/9958900/ea5a07d94414/medicina-59-00336-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4255/9958900/97eee23563c3/medicina-59-00336-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4255/9958900/ea5a07d94414/medicina-59-00336-g002.jpg

相似文献

1
Effect of Percutaneous Biliary Drainage on Enzyme Activity of Serum Matrix Metalloproteinase-9 in Patients with Malignant Hilar Obstructive Hyperbilirubinemia.经皮肝胆道引流术对恶性高位胆管梗阻性高胆红素血症患者血清基质金属蛋白酶-9 酶活性的影响。
Medicina (Kaunas). 2023 Feb 10;59(2):336. doi: 10.3390/medicina59020336.
2
[Treatment of refractory malignant biliary obstraction: comparing results of percutaneous transhepatic biliary drainage with external catheters or endoscopic metallic stenting].[难治性恶性胆管梗阻的治疗:经皮经肝胆道外引流管引流与内镜金属支架置入术的疗效比较]
Zhonghua Nei Ke Za Zhi. 2004 Feb;43(2):109-11.
3
Multicenter study of endoscopic preoperative biliary drainage for malignant hilar biliary obstruction: E-POD hilar study.多中心研究经内镜术前胆道引流治疗恶性肝门部胆道梗阻:E-POD 肝门部研究。
J Gastroenterol Hepatol. 2018 May;33(5):1146-1153. doi: 10.1111/jgh.14050. Epub 2018 Feb 21.
4
Percutaneous stent-in-stent placement with large cell-type stents for malignant hilar biliary obstruction.经皮支架内支架置入术联合大细胞型支架治疗恶性肝门部胆管梗阻。
Acta Radiol. 2021 Dec;62(12):1625-1631. doi: 10.1177/0284185120978512. Epub 2020 Dec 13.
5
Outcomes of Salvage Percutaneous Biliary Drainage after Occlusion of Endoscopic Stents.内镜支架闭塞后挽救性经皮胆道引流的结果
J Vasc Interv Radiol. 2017 Apr;28(4):594-601. doi: 10.1016/j.jvir.2016.12.1208. Epub 2017 Feb 4.
6
[Effect of preoperative biliary drainage on liver function changes in patients with malignant obstructive jaundice in the low bile duct before and after pancreaticoduodenectomy].[术前胆道引流对胰十二指肠切除术前低位胆管恶性梗阻性黄疸患者肝功能变化的影响]
Ai Zheng. 2008 Jan;27(1):78-82.
7
Palliation of Malignant Biliary Obstruction: Adverse Events are Common after Percutaneous Transhepatic Biliary Drainage.恶性胆道梗阻的姑息治疗:经皮经肝胆道引流后不良事件常见。
Scand J Surg. 2018 Mar;107(1):48-53. doi: 10.1177/1457496917731192. Epub 2017 Sep 25.
8
Safety and Efficacy of Percutaneous Biliary Covered Stent Placement in Patients with Malignant Biliary Hilar Obstruction; Correlation with Liver Function.经皮胆道覆膜支架置入术治疗恶性肝门部胆管梗阻的安全性和有效性;与肝功能的相关性
Cardiovasc Intervent Radiol. 2016 Sep;39(9):1298-305. doi: 10.1007/s00270-016-1375-5. Epub 2016 May 25.
9
Percutaneous transhepatic self-expanding metal stents for palliation of malignant biliary obstruction.经皮经肝自膨式金属支架用于恶性胆道梗阻的姑息治疗。
S Afr J Surg. 2012 Jul 11;50(3):54, 56, 58 passim. doi: 10.7196/sajs.1302.
10
Palliative percutaneous drainage in malignant biliary obstruction. Part 2: Mechanisms and postprocedure management.恶性胆管梗阻的姑息性经皮引流。第2部分:机制与术后管理。
J Support Oncol. 2006 Jul-Aug;4(7):329-35.

本文引用的文献

1
Total Fluoroscopy Time Reduction During Ultrasound- and Fluoroscopy-Guided Percutaneous Transhepatic Biliary Drainage Procedure: Importance of Adjusting the Puncture Angle.在超声和透视引导下经皮经肝胆道引流术中总透视时间的减少:调整穿刺角度的重要性。
Med Sci Monit. 2021 Nov 21;27:e933889. doi: 10.12659/MSM.933889.
2
Induction of synthesis of matrix metalloproteinases by interleukin-6; evidence for hepatic regeneration following hemi-hepatectomy.白细胞介素-6诱导基质金属蛋白酶的合成;半肝切除术后肝再生的证据。
Clin Exp Hepatol. 2020 Jun;6(2):137-141. doi: 10.5114/ceh.2020.95679. Epub 2020 May 27.
3
Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases.
基质金属蛋白酶作为肝脏疾病的潜在生物标志物和治疗靶点。
Cells. 2020 May 13;9(5):1212. doi: 10.3390/cells9051212.
4
Effects of 12-Week Exercise Program on Enzyme Activity of Serum Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Female Patients with Postmenopausal Osteoporosis: A Randomized Control Study.12 周运动方案对绝经后骨质疏松症女性患者血清基质金属蛋白酶-9 及组织金属蛋白酶抑制剂-1 酶活性的影响:一项随机对照研究。
Biomed Res Int. 2020 Jan 30;2020:9758289. doi: 10.1155/2020/9758289. eCollection 2020.
5
Inflammasome Is Activated in the Liver of Cholestatic Patients and Aggravates Hepatic Injury in Bile Duct-Ligated Mouse.在胆汁淤积患者的肝脏中炎症小体被激活,并在胆管结扎小鼠中加重肝损伤。
Cell Mol Gastroenterol Hepatol. 2020;9(4):679-688. doi: 10.1016/j.jcmgh.2019.12.008. Epub 2019 Dec 27.
6
The Versatile Role of Matrix Metalloproteinase for the Diverse Results of Fibrosis Treatment.基质金属蛋白酶在纤维化治疗结果多样性中的多功能作用。
Molecules. 2019 Nov 19;24(22):4188. doi: 10.3390/molecules24224188.
7
Percutaneous Biliary Interventions.经皮胆管介入治疗。
Gastroenterol Clin North Am. 2018 Sep;47(3):621-641. doi: 10.1016/j.gtc.2018.04.008. Epub 2018 Jul 7.
8
Liver-Selective MMP-9 Inhibition in the Rat Eliminates Ischemia-Reperfusion Injury and Accelerates Liver Regeneration.肝选择性 MMP-9 抑制可消除大鼠缺血再灌注损伤并加速肝再生。
Hepatology. 2019 Jan;69(1):314-328. doi: 10.1002/hep.30169. Epub 2018 Dec 20.
9
Kupffer-derived matrix metalloproteinase-9 contributes to liver fibrosis resolution.库普弗细胞衍生的基质金属蛋白酶-9有助于肝纤维化的消退。
Int J Biol Sci. 2018 Jun 3;14(9):1033-1040. doi: 10.7150/ijbs.25589. eCollection 2018.
10
Matrix Metalloproteinase-2 and -9, Lactate, and Malate Dehydrogenase and Lipid Peroxides in Sera of Patients with Colorectal Carcinoma.结直肠癌患者血清中的基质金属蛋白酶-2和-9、乳酸、苹果酸脱氢酶及脂质过氧化物
Folia Biol (Praha). 2017;63(5-6):190-196. doi: 10.14712/fb2017063050190.